Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced positive Phase 3 results for their dual-acting GLP-1/GIP receptor agonist, HRS9531, in Chinese patients with obesity. Trial participants achieved an average of 18% weight loss after 48 weeks compared with placebo, with nearly 90% losing at least 5% and 44% surpassing 20% weight reduction. The safety profile was consistent with mild to moderate gastrointestinal adverse events. Hengrui plans regulatory filings in China, while Kailera will expand global studies with higher doses and longer durations. The trial underscores China's growing influence in obesity drug development and licensing deals.